| EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S Gabriel, P Herman, ... Science 304 (5676), 1497-1500, 2004 | 11936 | 2004 |
| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4188 | 2010 |
| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ... New England Journal of Medicine 376 (7), 629-640, 2017 | 3329 | 2017 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1159 | 2007 |
| Abnormalities in structure and expression of the human retinoblastoma gene in SCLC JW Harbour, SL Lai, J Whang-Peng, AF Gazdar, JD Minna, FJ Kaye Science 241 (4863), 353-357, 1988 | 1116 | 1988 |
| Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. JM Horowitz, SH Park, E Bogenmann, JC Cheng, DW Yandell, FJ Kaye, ... Proceedings of the National Academy of Sciences 87 (7), 2775-2779, 1990 | 764 | 1990 |
| Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product WG Kaelin Jr, DC Pallas, JA DeCaprio, FJ Kaye, DM Livingston Cell 64 (3), 521-532, 1991 | 700 | 1991 |
| t (11; 19)(q21; p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway G Tonon, S Modi, L Wu, A Kubo, AB Coxon, T Komiya, K O'Neil, K Stover, ... Nature genetics 33 (2), 208-213, 2003 | 618 | 2003 |
| A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides FJ Kaye, PA Bunn Jr, SM Steinberg, JL Stocker, DC Ihde, AB Fischmann, ... New England Journal of Medicine 321 (26), 1784-1790, 1989 | 587 | 1989 |
| Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. SN Khleif, J Degregori, CL Yee, GA Otterson, FJ Kaye, JR Nevins, ... Proceedings of the National Academy of Sciences 93 (9), 4350-4354, 1996 | 507 | 1996 |
| Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. GA Otterson, RA Kratzke, A Coxon, YW Kim, FJ Kaye Oncogene 9 (11), 3375-3378, 1994 | 503 | 1994 |
| Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth WR Sellers, BG Novitch, S Miyake, A Heith, GA Otterson, FJ Kaye, ... Genes & development 12 (1), 95-106, 1998 | 413 | 1998 |
| Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups EA Sausville, JL Eddy, RW Makuch, AB Fischmann, GP Schechter, ... Annals of internal medicine 109 (5), 372-382, 1988 | 314 | 1988 |
| CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. GA Otterson, SN Khleif, W Chen, AB Coxon, FJ Kaye Oncogene 11 (6), 1211-1216, 1995 | 301 | 1995 |
| A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. FJ Kaye, RA Kratzke, JL Gerster, JM Horowitz Proceedings of the National Academy of Sciences 87 (17), 6922-6926, 1990 | 276 | 1990 |
| Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme L Rahman, D Voeller, M Rahman, S Lipkowitz, C Allegra, JC Barrett, ... Cancer cell 5 (4), 341-351, 2004 | 230 | 2004 |
| CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: Implications for histogenesis and … Y Tirado, MD Williams, EY Hanna, FJ Kaye, JG Batsakis, AK El‐Naggar Genes, Chromosomes and Cancer 46 (7), 708-715, 2007 | 212 | 2007 |
| Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial BC Creelan, C Wang, JK Teer, EM Toloza, J Yao, S Kim, AM Landin, ... Nature medicine 27 (8), 1410-1418, 2021 | 208 | 2021 |
| cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth Z Chen, JL Li, S Lin, C Cao, NT Gimbrone, R Yang, DA Fu, MB Carper, ... The Journal of clinical investigation 126 (6), 2267-2279, 2016 | 197 | 2016 |
| RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer FJ Kaye Oncogene 21 (45), 6908-6914, 2002 | 188 | 2002 |
